MX2021007222A - Factor i del complemento con optimizacion de codones. - Google Patents

Factor i del complemento con optimizacion de codones.

Info

Publication number
MX2021007222A
MX2021007222A MX2021007222A MX2021007222A MX2021007222A MX 2021007222 A MX2021007222 A MX 2021007222A MX 2021007222 A MX2021007222 A MX 2021007222A MX 2021007222 A MX2021007222 A MX 2021007222A MX 2021007222 A MX2021007222 A MX 2021007222A
Authority
MX
Mexico
Prior art keywords
optimised
codon
complement factor
cfi
nucleotide sequence
Prior art date
Application number
MX2021007222A
Other languages
English (en)
Inventor
Josephine Heather Lucienne Joel
Original Assignee
Gyroscope Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gyroscope Therapeutics Ltd filed Critical Gyroscope Therapeutics Ltd
Publication of MX2021007222A publication Critical patent/MX2021007222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un polinucleótido aislado que comprende una secuencia de nucleótidos que codifica un Factor I del complemento (CFI) con optimización de codones.
MX2021007222A 2018-12-21 2019-12-20 Factor i del complemento con optimizacion de codones. MX2021007222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1821089.8A GB201821089D0 (en) 2018-12-21 2018-12-21 Codon-optimised complement factor I
PCT/GB2019/053668 WO2020128516A2 (en) 2018-12-21 2019-12-20 Codon-optimised complement factor i

Publications (1)

Publication Number Publication Date
MX2021007222A true MX2021007222A (es) 2021-07-15

Family

ID=65364564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007222A MX2021007222A (es) 2018-12-21 2019-12-20 Factor i del complemento con optimizacion de codones.

Country Status (13)

Country Link
US (1) US20220073576A1 (es)
EP (2) EP3898660A2 (es)
JP (2) JP2022514595A (es)
KR (2) KR20210105925A (es)
CN (2) CN115927412A (es)
AU (2) AU2019411559A1 (es)
BR (1) BR112021011908A2 (es)
CA (1) CA3123750A1 (es)
GB (1) GB201821089D0 (es)
IL (2) IL284238A (es)
MX (1) MX2021007222A (es)
SG (1) SG11202106041SA (es)
WO (1) WO2020128516A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202009741D0 (en) 2020-06-25 2020-08-12 Freeline Therapeutics Ltd Polynucleotide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523640T3 (es) * 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
DK2191001T3 (en) 2007-04-09 2016-09-19 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
SG11201606983SA (en) * 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
US10293058B2 (en) * 2015-04-22 2019-05-21 Curevac Ag RNA containing composition for treatment of tumor diseases
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders

Also Published As

Publication number Publication date
JP2022514595A (ja) 2022-02-14
IL284238A (en) 2021-08-31
KR20210105925A (ko) 2021-08-27
CA3123750A1 (en) 2020-06-25
WO2020128516A3 (en) 2020-08-06
AU2019411559A1 (en) 2021-06-17
WO2020128516A2 (en) 2020-06-25
GB201821089D0 (en) 2019-02-06
EP4386085A2 (en) 2024-06-19
JP2024059871A (ja) 2024-05-01
CN115927412A (zh) 2023-04-07
SG11202106041SA (en) 2021-07-29
CN113383011A (zh) 2021-09-10
AU2023274191A1 (en) 2024-02-01
IL312657A (en) 2024-07-01
US20220073576A1 (en) 2022-03-10
BR112021011908A2 (pt) 2021-09-08
EP3898660A2 (en) 2021-10-27
KR20240037374A (ko) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2019015848A (es) Cubetas de lectura.
MX2022003859A (es) Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.
MX2020004287A (es) Procesamiento de biomasa.
TW201614647A (en) Memory with distributed replacement word lines
EP3996463C0 (en) MULTI-LEVEL SIDELINK CONTROL INFORMATION
MX2020003712A (es) Union giratoria de pasaje multiple.
MX2020004015A (es) Composicion de control de fraguado para sistemas cementosos.
IL281483A (en) Peptidase 9X-specific ubiquitin inhibition
GEP20247583B (en) Methods for treating condi tions associated with masp-2 dependent complement activation
CA185542S (en) Table
NZ735660A (en) Thiolene-based compositions with extended pot life
EP3852792A4 (en) INHIBITION OF UBIQUITIN-SPECIFIC PEPTIDASE 9X
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
MX2020003485A (es) Cambio del recurso de canal de control de enlace ascendente fisico (pucch).
IL312657A (en) Optimal codon for complement factor I
MX2020003707A (es) Instalacion de montaje de cabeza de pozo.
SG11202100058RA (en) Non-uv high hardness low k film deposition
MX2020004228A (es) Capa resistente al desgaste.
CL2018003838S1 (es) Botella.
EP3646522A4 (en) CHOICE OF CODE TYPES FOR ENCODING INFORMATION BITS
MX2017009952A (es) Metodo, aprato y sistema para ingresar caracteres.
MX2020004045A (es) Molecula inhibidora del acido nucleico de la catenina beta.
CA187846S (en) Inverter
MX2020004290A (es) Metodo para enfriar un proceso de polimerizacion.